UNSPSC 51132231: Aspirin/meprobamate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132231 Aspirin/meprobamate is a Commodity code that in practice encompasses a much broader range of pharmaceutical products and direct-to-manufacturer prescription programs than its nominal scope suggests. State and local governments soliciting under this code are acquiring generic multi-source pharmaceuticals, over-the-counter products, naloxone and drug deactivation systems, and exploring direct contracting models with pharmaceutical manufacturers to bypass traditional pharmacy benefit manager and wholesaler channels. Issuing bodies include state health and human services agencies, county public health departments, and multistate cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a repeat buyer establishing multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon.

Recent activity spans multiple states with significant concentration in Minnesota, Texas, and Florida. The Minnesota Department of Administration issued an RFP in January 2026 (due March 26, 2026) to establish generic pharmaceutical and OTC contracts through MMCAP, requiring vendor compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and partnerships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with contracts effective July 1, 2026. Seminole County, Florida posted IFB 60459723LAS in June 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, potentially funded through FEMA. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capability to establish direct contracts with self-insured plans and state agencies outside traditional PBM and GPO arrangements, signaling the state's intent to shift procurement models before issuing a formal RFP.